Pharmaceutical German drug developer Agennix is developing talactoferrin, a recombinant version of the human milk protein, lactoferrin, for the treatment of cancer and sepsis. These are potentially large indications with a high unmet medical need, and analysts at Edison Investment Research forecast that it could generate revenues of $2.5 billion if Phase III trials demonstrate the level of efficacy shown in Phase II trials. However, they say, in the short term, Agennix does need to raise between 60 million euros ($80.4 million) and 70 million euros. 1 April 2010